---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059667"
form_type: "8-K"
ticker: null
cik: "0001651407"
company_name: "Checkpoint Therapeutics, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T03:49:54.217338+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Checkpoint Therapeutics reports Q1 results; cosibelimab BLA resubmission targeted for mid-2024

## Summary
- Cash and equivalents $11.2M at March 31, 2024, up from $4.9M at Dec 31, 2023 after $14.0M offering.
- Net loss $10.9M ($0.33/sh) vs $10.5M ($0.89/sh) in Q1 2023; R&D expenses fell to $8.5M from $15.8M.
- Third-party CMO submitted response to FDA inspection deficiencies from Dec 2023 CRL; company plans FDA meeting for mid-year BLA resubmission.
- Board appointed Dr. Amit Sharma, VP at Alexion/AstraZeneca, as non-executive director in March 2024.

## SEC filing metadata
- accession: 0001104659-24-059667
- form_type: 8-K
- cik: 0001651407
- company_name: Checkpoint Therapeutics, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/0001104659-24-059667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/tm2413887d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059667
- JSON: https://secwatch.observer/filing/0001104659-24-059667.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059667.txt

## Key facts
- Earnings Releases
  Checkpoint Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $10.9 million, EPS $0.33 per share.
  - Period: first quarter ended March 31, 2024
  - Net income: $10.9 million
  - EPS: $0.33 per share
  - Result: reported results
  source text: Net loss attributable to common stockholders for the first quarter of 2024 was $10.9 million, or $0.33 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651407/000110465924059667/0001104659-24-059667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.